Sustained 9-CIS retinoic acid-eluting nanofiber scaffolds for enhanced lymphatic regeneration and lymphedema treatment
Active Grant Awarded Last action
- Award ID
- R41HL184685
- Recipient
-
Matregenix Inc. UEI HHSXEWBABG23
- Awarding agency
-
National Heart Lung and Blood Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $314,211
Award facts
- Assistance listing
- 93.837 Cardiovascular Diseases Research
- Completion date 24% complete
- Place of performance
- Irvine, CA 92617, USA
Award details come from USAspending.gov.
About this award
The Department of Health and Human Services, National Institutes of Health, National Heart, Lung, and Blood Institute awarded Matregenix Inc. $314,211 under the Cardiovascular Diseases Research program (CFDA 93.837) on August 21, 2026. The grant funds a Phase I study to develop a biodegradable, drug-eluting nanofiber scaffold, composed of amino acid-based poly(ester urea), that delivers sustained, localized 9-cis retinoic acid to promote lymphatic regeneration and treat lymphedema. Matregenix will fabricate flexible tubular scaffolds (roughly 1-2 mm inner diameter) on its proprietary electrospinning platform. The study has three aims: optimizing the formulation for target mechanical properties and 9-cis RA release over 4-8 weeks; evaluating biocompatibility and bioactivity with human lymphatic endothelial cells in vitro; and assessing efficacy in a murine hindlimb lymphedema model through imaging, histology, limb volume reduction, and lymphatic vessel regeneration. Phase I is designed to identify a lead scaffold formulation and demonstrate proof-of-concept efficacy in vitro and in vivo, setting up a Phase II program focused on large-animal studies and GLP-compliant biocompatibility testing. Work is performed in Irvine, California 92617. The award period runs from August 21, 2026 to an ultimate completion date of August 31, 2027. The assistance type is grant.
Description
- Abstract
- Lymphedema is a progressive and often irreversible condition characterized by impaired lymphatic drainage, chronic limb swelling, pain, and recurrent infections, affecting over 250 million individuals globally and more than 3 million in the united states. Despite its widespread impact and rising incidence in cancer survivors, no FDA-approved drug therapies exist to restore lymphatic function, and current treatment options-including compression garments and manual lymphatic drainage-are labor-intensive, lifelong, and fail to address the root cause of lymphatic vessel damage. To overcome this challenge, we propose the development of a biodegradable, drug-eluting nanofiber scaffold composed of amino acid-based poly(ester urea) (PEU) designed to deliver sustained, localized 9-CIS retinoic acid (9-CIS RA), a small molecule known to promote lymphangiogenesis. Leveraging matregenix's proprietary electrospinning platform, we will fabricate flexible, tubular scaffolds (~1-2 MM inner diameter) that provide both structural support and biochemical signaling to guide lymphatic regeneration. Our phase I study has three aims: (1) optimize the scaffold formulation to achieve target mechanical properties and sustained 9-CIS RA release over 4-8 weeks; (2) evaluate scaffold biocompatibility and bioactivity using human lymphatic endothelial cells in vitro, assessing viability, proliferation, migration, and tube formation; and (3) assess therapeutic efficacy in a murine hindlimb lymphedema model through imaging, histology, and functional endpoints such as limb volume reduction and lymphatic vessel regeneration. During phase I, we will identify a lead scaffold formulation and demonstrate proof-of-concept efficacy in vitro and in vivo. This will set the stage for a phase II program focused on large- animal studies, GLP-compliant biocompatibility testing, and regulatory engagement. We will initiate a pre- submission meeting with the FDA to determine the optimal regulatory pathway and define the required studies to support clearance or approval. This project represents a first-in-class approach to lymphatic repair, combining bioengineered structure with regenerative drug delivery, and has the potential to transform the standard of care for lymphedema by offering a functional, curative solution rather than lifelong symptom management.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Amendment | $0 | |
| Original award | $314,211 |
Quick answers
Who received award R41HL184685?
R41HL184685 was awarded to Matregenix Inc. by National Heart Lung and Blood Institute (National Institutes of Health) on August 21, 2026.
How much is award R41HL184685 worth?
$314,211 has been obligated on R41HL184685.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award